Distinctive genomic characteristics in POLE/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitor

Junjun He, Wei Ouyang, Wugan Zhao, Lin Shao, Bing Li, Bihao Liu, Dejuan Wang, Han Han-Zhang, Zhou Zhang, Liang Shao, Wencai Li